A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 08 Jan 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 04 Jan 2008 Status changed from in progress to completed.
- 10 Aug 2005 New trial record.